![Richard Bungay](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 4 987 $ in data 31/05/2026
Richard Edward Bungay is currently Director at Chroma Therapeutics Ltd. since 2004, Secretary & Director at Macrotarg Ltd. since 2011, Non-Executive Director at Nasdaq Corporate Solutions International Ltd., Non-Executive Director at Cambridge Cognition Holdings Plc since 2020, Secretary & Director at Diurnal Ltd., Director at Monument Therapeutics Ltd., and Chief Operating Officer at Sitala Bio Ltd. Former roles include Chief Executive Officer at Imophoron Ltd. from 2022 to 2024, Chief Financial Officer & Executive Director at Immedica Group Ltd. from 2017 to 2023, Finance Director-Respiratory & Inflammation Area at AstraZeneca PLC from 1998 to 2000, Director-Corporate Communications at Celltech Group Plc, Chief Financial Officer & Non-Executive Director at Glide Pharmaceutical Technologies Ltd., Chief Financial Officer at Verona Pharma Plc from 2013 to 2014, and Chief Operating & Financial Officer at Mereo BioPharma Group Plc.
Education includes an undergraduate degree from The University of Nottingham.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2024 | 10.000 ( 0,02% ) | 4 987 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CAMBRIDGE COGNITION HOLDINGS PLC | Direttore/Membro del Consiglio | 14/09/2020 |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Engages in the discovery and development of therapies for the treatment of cancer and inflammation | Direttore/Membro del Consiglio | 01/10/2004 |
Nasdaq Corporate Solutions International Ltd.
 Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Develops and manages software for corporate communications and reputation management solutions | Direttore/Membro del Consiglio | - |
Diurnal Ltd.
 Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Develops hormone therapeutics | Direttore/Membro del Consiglio | 18/01/2017 |
Macrotarg Ltd.
 Macrotarg Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Direttore/Membro del Consiglio | 04/05/2011 |
Monument Therapeutics Ltd.
 Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops precision medicines for central nervous system | Direttore/Membro del Consiglio | - |
Sitala Bio Ltd.
 Sitala Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops medicines for neurodegenerative and inflammatory diseases | Direttore operativo | - |
| Società | Posizione | Fine |
|---|---|---|
Imophoron Ltd.
 Imophoron Ltd. BiotechnologyHealth Technology Develops a novel vaccine platform for use on emerging infectious diseases | Amministratore Delegato | 01/12/2024 |
| DIUL GROUP | Amministratore Delegato | 01/02/2023 |
| ░░░░░ ░░░░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 15 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Engages in the discovery and development of therapies for the treatment of cancer and inflammation | Health Technology |
The University of Nottingham
 The University of Nottingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verona Pharma Plc
 Verona Pharma Plc Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of allergic rhinitis and other chronic respiratory diseases | Health Technology |
Glide Pharmaceutical Technologies Ltd.
 Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Diurnal Group Ltd.
 Diurnal Group Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and commercializes therapeutics for neuropsychiatric, neurological & neuroendocrine disorders | Health Technology |
Macrotarg Ltd.
Macrotarg Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
Nasdaq Corporate Solutions International Ltd.
Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Develops and manages software for corporate communications and reputation management solutions | Technology Services |
Cambridge Cognition Holdings Plc
 Cambridge Cognition Holdings Plc Packaged SoftwareTechnology Services Provides cognitive assessment software for clinical trials, academic research and healthcare provision | Technology Services |
Mereo BioPharma Group Plc
 Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Diurnal Ltd.
Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Develops hormone therapeutics | Health Technology |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops precision medicines for central nervous system | Health Technology |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Develops a novel vaccine platform for use on emerging infectious diseases | Health Technology |
Sitala Bio Ltd.
Sitala Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops medicines for neurodegenerative and inflammatory diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
